Zobrazeno 1 - 10
of 267
pro vyhledávání: '"Thatcher A."'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
JAMA Otolaryngol Head Neck Surg
Importance The use of intralesional cidofovir injections for recurrent respiratory papillomatosis (RRP) remains controversial owing to concern regarding the risks of its use, including increased risk of dysplasia or carcinogenesis. Objective To descr
Autor:
Egbert F. Smit, Thomas E. Stinchcombe, James R. Jett, David R. Gandara, David R. Spigel, Martin Reck, Fred R. Hirsch, Suresh S. Ramalingam, Ronald B. Natale, Mark A. Socinski, Edward S. Kim, Craig H. Reynolds, Corey J. Langer, Heather A. Wakelee, Jeffrey D. Bradley, Philip Bonomi, Luis Paz-Ares, Silvia Novello, Keith M. Kerr, Maurice Pérol, Nick Thatcher, Coleman K. Obasaju, Johan Vansteenkiste, Paul A. Bunn
Publikováno v:
Hirsch, F R, Kerr, K M, Bunn, P A, Kim, E S, Obasaju, C, Pérol, M, Bonomi, P, Bradley, J D, Gandara, D, Jett, J R, Langer, C J, Natale, R B, Novello, S, Paz-Ares, L, Ramalingam, S S, Reck, M, Reynolds, C H, Smit, E F, Socinski, M A, Spigel, D R, Stinchcombe, T E, Vansteenkiste, J F, Wakelee, H & Thatcher, N 2018, ' Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer : Effect of Current and Future Therapies and Technologies ', Clinical Lung Cancer, vol. 19, no. 4, pp. 331-339 . https://doi.org/10.1016/j.cllc.2018.03.014, https://doi.org/10.1016/j.cllc.2018.03.014
Patients with non-small-cell lung cancer, including squamous-cell lung cancer (SqCLC), typically present at an advanced stage. The current treatment landscape, which includes chemotherapy, radiotherapy, surgery, immunotherapy, and targeted agents, is
Autor:
David R. Spigel, Nick Thatcher, Edward S. Kim, Philip Bonomi, Melissa Culligan, Silvia Novello, C. Bellomo, Maurice Pérol, Paul A. Bunn, Martin Reck, Mark A. Socinski, Coleman K. Obasaju, Fred R. Hirsch, Johan Vansteenkiste, James R. Jett, Keith M. Kerr, Corey J. Langer, Heather A. Wakelee, Luis Paz-Ares, David R. Gandara, Craig H. Reynolds, Jeffrey D. Bradley, Suresh S. Ramalingam, Egbert F. Smit, Ronald B. Natale
Publikováno v:
Repisalud
Instituto de Salud Carlos III (ISCIII)
Bonomi, P D, Gandara, D, Hirsch, F R, Kerr, K M, Obasaju, C, Paz-Ares, L, Bellomo, C, Bradley, J D, Bunn, P A, Culligan, M, Jett, J R, Kim, E S, Langer, C J, Natale, R B, Novello, S, Pérol, M, Ramalingam, S S, Reck, M, Reynolds, C H, Smit, E F, Socinski, M A, Spigel, D R, Vansteenkiste, J F, Wakelee, H & Thatcher, N 2018, ' Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer ', Annals of Oncology, vol. 29, no. 8, pp. 1701-1709 . https://doi.org/10.1093/annonc/mdy196
Annals of Oncology
Instituto de Salud Carlos III (ISCIII)
Bonomi, P D, Gandara, D, Hirsch, F R, Kerr, K M, Obasaju, C, Paz-Ares, L, Bellomo, C, Bradley, J D, Bunn, P A, Culligan, M, Jett, J R, Kim, E S, Langer, C J, Natale, R B, Novello, S, Pérol, M, Ramalingam, S S, Reck, M, Reynolds, C H, Smit, E F, Socinski, M A, Spigel, D R, Vansteenkiste, J F, Wakelee, H & Thatcher, N 2018, ' Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer ', Annals of Oncology, vol. 29, no. 8, pp. 1701-1709 . https://doi.org/10.1093/annonc/mdy196
Annals of Oncology
The concept of predictive biomarkers for EGFR-directed mAbs addressed in this article were originally discussed at a meeting convened by Eli Lilly and Company that covered topics for physician education on SqCLC, for which participants, includ- ing s
Autor:
Nick, Thatcher, Fred R, Hirsch, Alexander V, Luft, Aleksandra, Szczesna, Tudor E, Ciuleanu, Mircea, Dediu, Rodryg, Ramlau, Rinat K, Galiulin, Beatrix, Bálint, György, Losonczy, Andrzej, Kazarnowicz, Keunchil, Park, Christian, Schumann, Martin, Reck, Henrik, Depenbrock, Shivani, Nanda, Anamarija, Kruljac-Letunic, Raffael, Kurek, Luis, Paz-Ares, Mark A, Socinski, Alexander, Spira
Publikováno v:
The Lancet Oncology. 16:763-774
Background: Necitumumab is a second-generation, recombinant, human immunoglobulin G1 EGFR antibody. In this study, we aimed to compare treatment with necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone in patients with p
Autor:
Luis Paz-Ares, Rebecca R. Hozak, Gu Mi, Marileila Varella-Garcia, Carlo Genova, Fred R. Hirsch, Javad Shahidi, Nick Thatcher, Christopher J. Rivard, Mark A. Socinski, Raffael Kurek
Introduction Necitumumab is a monoclonal antibody targeting EGFR. In the SQUIRE trial, the addition of necitumumab to chemotherapy for squamous cell lung cancer significantly improved overall survival (OS) (hazard ratio [HR] = 0.84); in a post hoc an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7d38f44bff719dcf2642bd59eb8fc86
https://europepmc.org/articles/PMC6233716/
https://europepmc.org/articles/PMC6233716/
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Frank Griesinger, Ashis Das-Gupta, J. De Castro Carpeno, AM Dingemans, Vlatka Smoljanovic, Cesare Gridelli, Margarita Donica, Yuichiro Ohe, Francesco Grossi, Corey J. Langer, Kostas N. Syrigos, Nick Thatcher, Jaafar Bennouna
Publikováno v:
Pneumologie. 72:S39-S40
Autor:
Cesare Gridelli, Yuichiro Ohe, Jaafar Bennouna, Ashis Das-Gupta, Nick Thatcher, Margarita Donica, Francesco Grossi, Matt Truman, Konstantinos N. Syrigos, Javier de Castro Carpeño, Frank Griesinger, Anne-Marie C. Dingemans, Corey J. Langer, Vlatka Smoljanovic
Publikováno v:
JAMA Oncology, 4(12):183486. American Medical Association
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Importance Bevacizumab treatment beyond progression has been investigated in breast and metastatic colorectal cancers. Avastin in All Lines Lung (AvaALL) is the first randomized phase 3 study of bevacizumab across multiple lines of treatment beyond p
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.